196. Norovirus
Saturday, October 10, 2015: 8:30 AM-10:00 AM
Room: 29--ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe strategies for protecting vulnerable populations form norovirus infection
  • identify adaptive and genetic bases for resistance to norovirus infection and illness
  • discuss the status of norovirus vaccine development and remaining hurdle to licensure

Target Audience: Vaccinologists, Scientists, Researchers, Public health practitioners, Nurses, Members-in-training, Medical students and residents, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, HIV specialists, HIV clinicians, Healthcare workers, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID, Trainee

Moderators:  Robert Atmar, MD, FIDSA, FSHEA, Baylor College of Medicine and Benjamin Lopman, PhD, MSc, Centers for Disease Control and Prevention

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-191-L01-P


R. Atmar, Takeda Vaccines, Inc.: Consultant and Investigator , Research grant

B. Lopman, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.